跳至內容

布瑞哌唑

維基百科,自由的百科全書
布瑞哌唑
臨床資料
讀音/brɛkˈspɪprəzl/ brek-SPIP-rə-zohl
商品名英語Drug nomenclatureRexulti, Rxulti, others
其他名稱OPC-34712
AHFS/Drugs.comMonograph
MedlinePlusa615046
核准狀況
懷孕分級
給藥途徑口服給藥
藥物類別非典型抗精神病藥物
ATC碼
法律規範狀態
法律規範
藥物動力學數據
生物利用度95% (T最大 = 4 小時)[9]
血漿蛋白結合率>99%
藥物代謝肝臟 (主要透過CYP3A4CYP2D6)
生物半衰期91 小時 (布瑞哌唑), 86 小時 (主要代謝物)
排泄途徑糞便 (46%), 尿液 (25%)
識別資訊
  • 7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]quinolin-2(1H)-one
CAS號913611-97-9
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.242.305 編輯維基數據鏈接
化學資訊
化學式C25H27N3O2S
摩爾質量433.57 g·mol−1
3D模型(JSmol英語JSmol
  • O=C5/C=C\c4ccc(OCCCCN3CCN(c1cccc2sccc12)CC3)cc4N5
  • InChI=1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29)
  • Key:ZKIAIYBUSXZPLP-UHFFFAOYSA-N

布瑞哌唑INN:Brexpiprazole)是一種非典型抗精神病藥物,用於治療精神分裂症重性抑鬱障礙[12]。需用於12歲以上的精神分裂症患者[12]。也用於治療失智症患者的躁動英語Agitation[13]。口服使用[14]

常見副作用包括體重增加和動作障礙疾病英語Movement disorder(即靜坐不能[12]。其他副作用包括可能抗精神藥物惡性症候群遲發性運動不能糖尿病、賭博問題和白血球減少症[12]。用於老年失智症患者會增加死亡風險[12]。孕期安全性不明[15]。一般認為它會影響大腦中的多巴胺血清素去甲腎上腺素[14]


參考文獻

[編輯]
  1. ^ Brexpiprazole (Rexulti) Use During Pregnancy. Drugs.com. 10 February 2020 [18 August 2020]. 
  2. ^ 2.0 2.1 Rexulti brexpiprazole 4 mg film coated tablets blisters (273224). Therapeutic Goods Administration英語Therapeutic Goods Administration (TGA). [26 February 2023]. 
  3. ^ AusPAR: Brexpiprazole
  4. ^ Prescription medicines: registration of new chemical entities in Australia, 2017. Therapeutic Goods Administration (TGA). 21 June 2022 [9 April 2023]. 
  5. ^ Prescription medicines and biologicals: TGA annual summary 2017. Therapeutic Goods Administration (TGA). 21 June 2022 [31 March 2024]. 
  6. ^ Rexulti Product information. Health Canada. [26 February 2023]. 
  7. ^ Rexulti monograph
  8. ^ Mental health. Health Canada. 9 May 2018 [13 April 2024]. 
  9. ^ 9.0 9.1 Rexulti- brexpiprazole tablet Rexulti- brexpiprazole kit. DailyMed. 21 February 2023 [26 February 2023]. 
  10. ^ Rxulti EPAR. European Medicines Agency (EMA). 17 September 2018 [26 February 2023].  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  11. ^ Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União英語Diário Oficial da União. 31 March 2023 (4 April 2023) [16 August 2023]. (原始內容存檔於3 August 2023) (巴西葡萄牙語). 
  12. ^ 12.0 12.1 12.2 12.3 12.4 DailyMed - REXULTI- brexpiprazole tablet. dailymed.nlm.nih.gov. [11 January 2022]. (原始內容存檔於11 May 2021). 
  13. ^ Drug to treat agitation in Alzheimer’s patients approved in Canada - National | Globalnews.ca. Global News. January 25, 2024 [26 January 2024]. (原始內容存檔於26 January 2024). 
  14. ^ 14.0 14.1 Rxulti. [11 January 2022]. (原始內容存檔於12 January 2022). 
  15. ^ Brexpiprazole (Rexulti) Use During Pregnancy. Drugs.com. [11 January 2022]. (原始內容存檔於5 December 2020) (英語). 

外部連結

[編輯]

#invoke:navbox